Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma

International Journal of Cancer

Volumn 67, Issue 4, 1996, Pages 580-585

  Baral, Edward ^b   Nagy, Eva ^a   Kangas, Lauri ^c   Berczi, Istvan ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Manitoba Cancer Treatment and Research Foundation   (Canada)

^c ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TOREMIFENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG SCREENING; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MASTOCYTOMA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; COMBINED MODALITY THERAPY; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; MAST-CELL SARCOMA; MICE; MICE, INBRED DBA; RECOMBINANT PROTEINS; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS; TOREMIFENE;

EID: 0029833920     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960807)67:4<580::AID-IJC18>3.0.CO;2-B     Document Type: Article

References (23)

1. ALBERTINI, M.R., GIBSON, D.F.C., ROBINSON, S.P., HOWARD, S.P., TANS, K.J., LINDSTROM, M.J., ROBINSON, R.R., TORMEY, D.C., JORDAN, V.C. and SONDEL, P.M., Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells. J. Immunother., 11, 30-39 (1992).
2. BARAL, E., KWOK, S. and BERCZI, I., Suppression of lymphocyte mitogenesis by tamoxifen. Immunopharmacology, 18, 57-62 (1989).
3. BARAL, E., KWOK, S. and BERCZI, I., The influence of estradiol and tamoxifen on the mixed lymphocyte reaction in rats. Immunopharmacology, 21, 191-198 (1991).
4. BARAL, E., NAGY, E. and BERCZI, I., Tamoxifen as an immunomodulatory agent. In: Berczi, I. and Szelenyi, J. (eds.), Advances in psychoneuroimmunology, pp. 233-241, Plenum Press, New York (1994a).
5. BARAL, E., NAGY, E. and BERCZI, I., Target cells are sensitized for cytotoxic T-lymphocyte-mediated destruction by estradiol and tamoxifen. Int. J. Cancer, 57, 1-5 (1994b).
6. BARAL, E., NAGY, E. and BERCZI, I., Enhancement of natural killer cell mediated cytotoxicity by tamoxifen. Cancer, 75, 591-599 (1995).
7. BARAL, E., NAGY, E. and BERCZI, I., Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen. Int. J. Cancer, 65, 1-5 (1996a).
8. BARAL, E., NAGY, E. and BERCZI, I., The effect of tamoxifen on the immune response. In: J. A. Kellen (ed.), Tamoxifen: beyond the antiestrogen, Birkhauser, Boston, MA (1996b). (in press).
9. BARAL, E. and VANKY, F., Effect of tamoxifen on the cell-mediated autotumor lysis. J clin. Lab. Immunol., 22, 97-100 (1987).
10. BERCZI, I., Studies in tumor immunology. Ph.D. thesis, The University of Manitoba (1972).
11. BERCZI, I., Cancer immunology - quo vadis? An overview. J. Exp. Clin. Cancer Res., 2, 135-144 (1983).
12. BERCZI, I., BARAL, E. and NAGY, E., The amplification of cell-mediated cytolysis by estradiol and tamoxifen (Abstract). Proc. 8th International Congress of Immunology, Budapest, Hungary (1992).
13. BERCZI, I. and SEHON, A.M., Tumor inhibition by effector cells cultured from progressing sarcomas. Immunol. Commun., 6, 617-632 (1977).
14. BERCZI, I. and SEHON, A.H., Effector and suppressor lymphoid cells in tumor bearing guinea pigs. Int. J. Cancer, 23, 274-282 (1979).
15. BERCZI, I., STRAUSBAUCH, P. and SEHON, A.H., Rejection of tumor cells in vitro. Science, 180, 1289-1291 (1973).
16. HELLSTRÖM, I. and HELLSTRÖM, K.E., Tumor immunology: an overview. Ann. N.Y. Acad. Sci., 690, 24-33 (1993).
17. MANDEVILLE, R., GHALLI, S.S. and CHAUSSEAU, J.-P., In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Europ. J. Cancer clin. Oncol., 20, 983-985 (1984).
18. NAGY, E. and BERCZI, I., Immunomodulation by tamoxifen and pergolide. Immunopharmacology, 12, 145-153 (1986).
19. PAAVONEN, T. and ANDERSSON, L.C., The estrogen antagonists, tamoxifen and FC-1157a, display oestrogen like effects on human lymphocyte functions in vitro. Clin. exp. Immunol., 61, 467-474 (1985).
20. ROSENBERG, S.A., LOTZE, M.T., MUUL, L.M., CHANG, A.E., AVIS, F.P., LEITMAN, S. et al., A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high-dose interleukin 2 alone. New Engl. J. Med., 316, 889-897 (1987).
21. ROSENBERG, S.A., LOTZE, M.T., MUUL, L.M., LEITMAN, S., CHANG, A.E., ETTINGHAUSEN, S.E. et al., Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. New Engl. J. Med., 313, 1485-1492 (1985).
22. WANG, K.C., BERCZI, I., HOFFMAN, E.G. and SEHON, A.H., Effector and enhancing lymphoid cells in plasmacytoma bearing mice. II. Dynamic changes during tumor progression. Int. J. Cancer, 25, 493-501 (1980a).
23. WANG, K.C., BERCZI, I. and SEHON, A.H., Effector and enhancing lymphoid cells in plasmacytoma bearing mice. I. Methodological studies on the Winn assay. Int. J. Cancer, 25, 487-492 (1980b).